Table 2.
Healing rates of duodenal ulcers up to week 4 in the FAS and PPS populations.
| Treatment | FAS population | PPS population | ||
|---|---|---|---|---|
| Independent central review | Investigator review | Independent central review | Investigator review | |
| Healing rates | ||||
| Rabeprazole 10 mg [No.] [(%) (95% CI)] | 44 [88.0 (79.0–97.0)] | 36 [72.0(59.6–84.5)] | 40 [88.9(79.7–99.4)] | 34 [75.6(63.0–88.1)] |
| Anaprazole 20 mg [No. ] [(%) (95% CI)] | 40 [85.1(74.9–95.3)] | 33 [70.2(57.1–83.3)] | 37 [86.0(75.7–96.4)] | 31 [72.1(58.7–85.5)] |
| Anaprazole 40 mg [No. ] [(%) (95% CI)] | 42 [87.5(78.1–96.9)] | 37 [77.1(65.2–89.0)] | 40 [90.9(82.4–99.4)] | 35 [79.5(67.6–91.5)] |
| Difference in healing rate between groups | ||||
| Anaprazole 20 mg-Rabeprazole 10 mg [% (95% CI)] | −2.9 (−16.5–10.7) | −1.8 (−19.8–16.3) | −2.8 (−16.7–11.0) | −3.5 (−21.8–14.9) |
| Anaprazole 40 mg-Rabeprazole 10 mg [% (95% CI)] | −0.5 (−13.5–12.5) | 5.1 (−12.2–22.3) | 2.0 (−10.5–14.5) | 4.0 (−13.4–21.3) |
| Anaprazole 20 mg-Anaprazole 40 mg [% (95% CI)] | 2.4 (−11.4–16.2) | 6.9 (−10.8–24.6) | 4.9 (−8.5–18.3) | 7.5 (−10.5–25.4) |
FAS, full analysis set; PPS, per-protocol set; CI, confidence interval. Farrington-Manning analysis was used to assess the differences in healing rates between groups with the 95% confidence interval (95% CI).